Ascendis Pharma reported positive five-year results from its Phase 2 PaTH Forward trial of TransCon PTH (palopegteriparatide) for adult hypoparathyroidism. The therapy maintained stable calcium levels, kidney and bone health, and quality of life, allowing most patients to stop conventional treatments. Key outcomes included 82% of patients meeting treatment goals, improved kidney function, and sustained symptom relief. The treatment was well tolerated with no new safety concerns, leading to a 3.6% stock rise to $223.37.
The Touchstone Mid Cap Growth Fund (Class A Shares, Load Waived) outperformed its benchmark, the Russell Midcap Growth Index, for the quarter ended March 31, 2026. Key contributors to this strong performance included Vertiv Holdings, Ascendis Pharma,...
Ascendis Pharma announced 5-year Phase 2 trial results for TransCon PTH, showing sustained efficacy and safety in adults with hypoparathyroidism. The treatment replicated natural parathyroid hormone effects, improving kidney function, calcium levels,...
Ascend Learning's ATI Engage® Series won the Digital Learning Innovation Award at the 2026 EdTech Breakthrough Awards for its advanced digital platform that enhances nursing education. The platform uses AI to personalize learning, offering interactiv...
Ascendis Pharma announced it will share new clinical trial data on treatments for rare endocrine diseases including hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency at the ENDO 2026 conference in Chicago. The presentations ...
